1. Home
  2. TARS vs GDRX Comparison

TARS vs GDRX Comparison

Compare TARS & GDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TARS
  • GDRX
  • Stock Information
  • Founded
  • TARS 2016
  • GDRX 2011
  • Country
  • TARS United States
  • GDRX United States
  • Employees
  • TARS N/A
  • GDRX N/A
  • Industry
  • TARS Medicinal Chemicals and Botanical Products
  • GDRX Retail: Computer Software & Peripheral Equipment
  • Sector
  • TARS Health Care
  • GDRX Technology
  • Exchange
  • TARS Nasdaq
  • GDRX Nasdaq
  • Market Cap
  • TARS 2.0B
  • GDRX 1.7B
  • IPO Year
  • TARS 2020
  • GDRX 2020
  • Fundamental
  • Price
  • TARS $47.84
  • GDRX $4.81
  • Analyst Decision
  • TARS Strong Buy
  • GDRX Buy
  • Analyst Count
  • TARS 6
  • GDRX 15
  • Target Price
  • TARS $56.00
  • GDRX $8.75
  • AVG Volume (30 Days)
  • TARS 460.8K
  • GDRX 924.9K
  • Earning Date
  • TARS 02-25-2025
  • GDRX 02-27-2025
  • Dividend Yield
  • TARS N/A
  • GDRX N/A
  • EPS Growth
  • TARS N/A
  • GDRX N/A
  • EPS
  • TARS N/A
  • GDRX N/A
  • Revenue
  • TARS $129,621,000.00
  • GDRX $790,385,000.00
  • Revenue This Year
  • TARS $921.89
  • GDRX $7.89
  • Revenue Next Year
  • TARS $85.83
  • GDRX $4.03
  • P/E Ratio
  • TARS N/A
  • GDRX N/A
  • Revenue Growth
  • TARS 801.96
  • GDRX 7.14
  • 52 Week Low
  • TARS $20.08
  • GDRX $4.09
  • 52 Week High
  • TARS $57.28
  • GDRX $9.26
  • Technical
  • Relative Strength Index (RSI)
  • TARS 39.21
  • GDRX 48.79
  • Support Level
  • TARS $49.86
  • GDRX $4.98
  • Resistance Level
  • TARS $53.22
  • GDRX $5.25
  • Average True Range (ATR)
  • TARS 2.44
  • GDRX 0.19
  • MACD
  • TARS -0.56
  • GDRX -0.00
  • Stochastic Oscillator
  • TARS 7.09
  • GDRX 33.33

About TARS Tarsus Pharmaceuticals Inc.

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.

About GDRX GoodRx Holdings Inc.

GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.

Share on Social Networks: